| Outcome Measures: |
Primary: Serum phosphorus (mmol/l ), Change from baseline in serum phosphorus levels at Week 12: comparison between PA21 group and sevelamer carbonate group., baseline and 12 weeks | Secondary: Serum phosphorus (mmol/l ), Serum phosphorus levels at each time point and change from baseline (BL), baseline, weeks 1, 2, 4, 6, 8, 12|Serum phosphorus (mmol/l), % of subjects with serum phosphorus within 1.13 to 1.78 mmol/l, baseline, weeks 1, 2, 4, 6, 8, 12|Adverse events (AEs), Frequency of AEs determined by seriousness, severity and relatedness to study drugs, baseline, weeks 1, 2, 4, 6, 8, 12|Diarrhoea., Frequency of AE of special interest - diarrhoea., baseline, weeks 1, 2, 4, 6, 8, 12|Withdrawals due to AEs, Percentage of withdrawals due to AEs, baseline, weeks 1, 2, 4, 6, 8, 12|Serum calcium (mmol/l), Serum total calcium levels at each time point and change from baseline, baseline, weeks 1, 2, 4, 6, 8, 12|Hypercalcemia (mmol/l), Percentage of subjects that develop at least 1 episode of sustained hypercalcaemia (\>10.0 mg/dl; \>2.5 mmol/l) during study participation, baseline, weeks 1, 2, 4, 6, 8, 12|Serum iPTH (pg/ml), Serum iPTH levels at specified time points and change from baseline, baseline, weeks 8, 12|Serum iron (mcg/dl), Serum iPTH levels at specified time points and change from baseline, baseline, weeks 4, 8, 12|Serum ferritin (mcg/l), Serum ferritin levels at specified time points and change from baseline, baseline, weeks 4, 8, 12|Serum transferrin (mcg/dl), Serum transferrin measured at specified timepoints, baseline, weeks 4, 8, 12|Transferrin saturation (TSAT) (%), TSAT measured at specified timepoints, baseline, weeks 4, 8, 12
|
